Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients

Multiple myeloma (MM) patients who become refractory to anti-MM drugs have a very poor prognosis. Therefore, it is important to gain insight into the mechanisms of resistance to these drugs. Immunomodulatory drugs (IMiDs) have immune-stimulatory and anti-angiogenic properties as well as direct anti-

• Publication year

  2018

• Venue

  Haematologica

• Publication date

  2018-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.3324/haematol.2017.186601PMID 29545338PMCID PMC6068039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner

  2017cited by this paper
• Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

  2016cited by this paper
• Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

  2016cited by this paper
• Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial

  2016cited by this paper
• A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples

  2016cited by this paper
• Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT.

  2016cited by this paper
• Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

  2016cited by this paper
• Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

  2015cited by this paper
• Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

  2014cited by this paper
• The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

  2014cited by this paper
• High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

  2013cited by this paper
• Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

  2013cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  2012cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

  2011cited by this paper
• Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

  2011cited by this paper
• Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

  2007cited by this paper

• Application of Weighted Interaction-Fingerprints for Rationalizing Neosubstrate Potency and Selectivity of Cereblon-Based Molecular Glues.

  2025cites this paper
• Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics

  2025cites this paper
• Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities

  2025cites this paper
• Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs

  2025cites this paper
• Exploration of degrons and their ability to mediate targeted protein degradation.

  2025cites this paper
• Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity.

  2025cites this paper
• From serendipity to strategy: molecular glue degraders in cancer therapeutics

  2025cites this paper
• Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma.

  2024cites this paper
• Beneficial Effect of Olive Oil and Its Derivates: Focus on Hematological Neoplasm

  2024cites this paper
• Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

  2024influential citation
• Decreased RNA‐binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide

  2024cites this paper
• The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

  2024cites this paper
• Sustained yet non-curative response to lenalidomide in relapsed angioimmunoblastic T-cell lymphoma with acquired chidamide resistance: a case report with 10-year follow-up, genetic insights and literature review

  2024cites this paper
• Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond

  2024cites this paper
• Targeting the ubiquitin pathway in lymphoid malignancies.

  2024cites this paper
• Identification of novel GSPT1 degraders by virtual screening and bioassay.

  2024cites this paper
• Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

  2024cites this paper
• MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products

  2023cites this paper
• IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?

  2023cites this paper
• High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients

  2023cites this paper
• Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives

  2023cites this paper
• SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide

  2022cites this paper
• Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

  2022cites this paper
• Transcriptional profiles define drug refractory disease in myeloma

  2022cites this paper
• The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma

  2022cites this paper
• SimPLIT: Simplified Sample Preparation for Large-Scale Isobaric Tagging Proteomics

  2022cites this paper
• Targeting cereblon in hematologic malignancies.

  2022cites this paper
• CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma

  2022cites this paper
• The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease

  2022cites this paper
• Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation

  2021cites this paper
• The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

  2021cites this paper
• Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma.

  2021cites this paper
• ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment

  2021cites this paper
• From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins

  2021cites this paper
• Lenalidomide

  2021cites this paper
• Mutation-dependent treatment approaches for patients with complex multiple myeloma

  2021influential citation
• Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma

  2021cites this paper
• Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

  2021cites this paper
• Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

  2021cites this paper
• Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

  2021cites this paper
• miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma

  2021cites this paper
• Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity

  2021cites this paper
• Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity

  2021cites this paper
• Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells

  2021cites this paper
• Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

  2020cites this paper
• Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

  2020cites this paper
• A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

  2020cites this paper
• Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma.

  2020cites this paper
• Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma

  2020cites this paper
• A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.

  2020cites this paper
• The application of ubiquitin ligases in the PROTAC drug design.

  2020cites this paper
• Successful Clinical Sequencing by Molecular Tumor Board in an Elderly Patient With Refractory Sézary Syndrome.

  2020cites this paper
• c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

  2020cites this paper
• Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

  2020cites this paper
• Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

  2019cites this paper
• Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

  2019cites this paper
• Patterns of substrate affinity, competition and degradation kinetics underlie biological activity of thalidomide analogs.

  2019cites this paper
• Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

  2018cites this paper
• Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale

  2018cites this paper
• Patterns of substrate a ffi nity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

  year unknowncites this paper